🇺🇸

Index Intelligence

· daily

S&P 500 Industrials Sector SEC Filings — April 30, 2026

Across 50 SEC filings from S&P 500 Industrials and adjacent sectors for Q1 2026 (period ending ~March 31, 2026), mixed sentiment prevails in 70% of material reports, with 18/25 key quarterly earners showing average revenue growth of 12% YoY (range -30% to +27%) but margin compression in 14 cases averaging -150 bps YoY due to cost inflation, impairments, and weather disruptions. Industrials like Caterpillar (+22% sales), Trane Technologies (+6% revenues, record backlog +30%), and L3Harris (+12% revenue, backlog $40.7B) highlight robust demand in construction, HVAC, and defense, offset by softer Resource Industries and EMEA. Capital allocation trends strongly favor shareholders with $12B+ in buybacks/dividends across 15 firms (e.g., Caterpillar $5B, Newmark 10.4M shares), while M&A activity surges (e.g., Pioneer Bancorp acquisitions, Martin Marietta New Frontier deal). Guidance raised in 9 companies (e.g., Trane to 9.5% growth, L3Harris EPS +$0.10), signaling conviction amid geopolitical risks. Banks exhibit NIM stability (avg +5 bps QoQ) but deposit/loan volatility; non-industrials like Alphabet (+22% revenue) provide relative outperformance benchmarks. Portfolio implication: overweight defensive industrials with strong backlogs/book-to-bills >1.2x, monitor margin recovery catalysts.

12 high priority 38 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — April 30, 2026

Across 20 SEC filings from the USA S&P 500 Energy stream (including contextual non-energy for completeness), Q1 2026 results show mixed performance with average revenue growth of ~14% YoY where reported (Valero +7%, CommScope +21.6%, SunCoke +4%, Southern Copper +36.2%, offset by ConocoPhillips -5%), but profitability trends divergent: strong turnarounds (Valero from loss to $1.26B NI) contrasted by declines (Conoco NI -23%, SunCoke op inc -85%). Capital allocation remains shareholder-friendly, with $ billions returned via dividends/buybacks (Conoco $2B Q1, Valero $923M Q1 treasury+div, CommScope $10/share special dist). M&A/divestitures drive gains (CommScope $5.3B discontinued ops gain from CCS sale, RUCKUS to Belden $1.846B; SunCoke Phoenix acquisition adding $63M rev). Energy sector faces production headwinds (Conoco -3% YoY to 2.3MMBOED, Ecopetrol slight dip) but stable guidance (SunCoke FY adj EBITDA $230-250M reaffirmed, Conoco FY prod 2.295-2.325MMBOED). Sentiment mixed overall (9/20 mixed), with outliers in refining/metals shining; portfolio implication: favor capital returners amid volatile ops metrics.

10 high priority 10 medium 20 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 30, 2026

Across 50 SEC filings for the USA Dow Jones 30 intelligence stream (period April 30, 2026), Q1 2026 results dominate with 25+ earnings reports showing aggregate revenue growth of ~12% YoY (e.g., Caterpillar +22%, Quanta +26%, Merck +5%) but mixed profitability due to one-offs like impairments (Bausch $1.4B goodwill) and R&D spikes (Viking +263%). Margin trends reveal compression in 14/30 high-materiality filers (avg -150 bps, e.g., CNH Ag 440 bps drop), offset by expansions in banks (Pioneer NIM +9 bps) and insurers (Hippo combined ratio -60 pts). M&A activity surges with 12+ deals (e.g., Nvni 7 acquisitions, Pioneer 3), while capital allocation favors returns (18/50 announce buybacks/dividends, e.g., Southside $0.36 div, Quanta raised guidance). Guidance raised in 10/20 cases (e.g., Hippo GWP +$25-75M, Indivior rev +$90-90M), signaling resilience amid macro headwinds. Biotech fundraises extend runways (Intellia to 2028), but ongoing losses flag cash burn risks. Portfolio implication: overweight industrials (backlogs $48B Quanta), monitor banks for NIM/expenses, avoid high-impairment pharma.

14 high priority 36 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 30, 2026

Across 50 SEC filings from S&P 500 Consumer Discretionary (retail, auto, hospitality, entertainment), Q1 2026 results show robust revenue growth averaging 8-12% YoY in key reporters like Amazon (+16.6%), Meta (+33.1%), Ford (+6.4%), Chipotle (+7.4%), and Wayfair (+7.4%), driven by pricing, volume, and services, but offset by margin compression (e.g., Chipotle ops income -17.1%, Builders gross margin -220 bps) from labor/food costs and capex surges (Amazon +76.7% YoY, Meta +46.7%). Capital allocation remains shareholder-friendly with aggressive buybacks (Chipotle $755M, Hilton $150M, PBF $9M) and dividends (e.g., Ford cut but others up), alongside positive financing (Bob's +$75M revolver to $200M, FTAI Aviation to $2.025B) and M&A (MARA $1.5B acquisition, FTAI sale $1.52B). Mixed sentiment prevails (28/50 mixed), with bullish expansions (AITX hospitality, Amazon services +20.2%) contrasting deteriorations (Smurfit net income -83.5%, OneWater rev -8.5%); forward guidance mostly reaffirmed or raised (Hilton EBITDA to $1.225-1.265B, Diebold full-year outlook). Insider conviction mixed (Tesla Musk 413M shares held, Apollo stable holdings), no major sells flagged. Portfolio implication: Favor high-growth retail/tech like Amazon/Meta over cyclical auto/construction amid cost pressures; watch Q2 catalysts for margin recovery.

22 high priority 28 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 30, 2026

Across 50 SEC filings from the USA S&P 500 Healthcare stream (though including cross-sector noise), Q1 2026 results show mixed performance with 12/20 earnings reporters posting YoY revenue growth averaging +20% (led by Eli Lilly +56%, Newmark +27%), but 8/20 facing margin compression or one-off losses (avg -150bps EBITDA margins in mixed filers like Merck, Baxter). Healthcare standouts include Eli Lilly's blockbuster-driven surge (Mounjaro +125% YoY) and Cigna's raised FY2026 EPS guidance to $30.35+, contrasting softer organic growth in Baxter (-1%) and Pacira's reiterated flat outlook; non-healthcare like Newmark and LPL Financial highlight capital return strength via buybacks/dividends. Forward-looking catalysts cluster in May-Jun 2026 (Merck Terns acquisition close, multiple AGMs), with 6/50 flagging raised guidance and 7/50 noting buybacks totaling >$2B (e.g., CPKC $680M Q1). Insider activity sparse (mostly neutral 13Fs showing institutional conviction in tech/health ETFs), but capital allocation trends bullish (dividend hikes in 5/50, e.g., Newmark to $0.06). Portfolio implication: overweight pharma growth names amid efficiency gains (Cigna SG&A -100bps), monitor margin pressures and M&A integration risks.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 29, 2026

Across 43 filings from S&P 500 Technology stream (with broader exposure via 13Fs and proxies), dominant themes include robust cloud/AI growth in Microsoft (revenue +18% YoY, Azure +40%, AI run-rate +123% to $37B) contrasting mixed semiconductor results like Qualcomm's -3% YoY revenue amid handset weakness but +38% Automotive. Period-over-period trends show 4/6 key tech firms with double-digit YoY revenue growth (avg +14%), margin stability or expansion in leaders like KLA (+11.8% non-GAAP EPS), aggressive capital returns ($10.2B Microsoft, $20B new Qualcomm buyback, $7B KLA), and raised guidance (SBA FY AFFO/share, KLA Q4 revenue). Institutional 13Fs highlight sustained tech conviction (R Squared $4.78B Apple/$2.62B MSFT, Vanguard 7.48% Apple). Non-tech filings reveal dividend hikes (CPKC +17.5%, KLA to $2.30, ACNB $0.42+$0.50 special) but declines elsewhere (Cumulus -12.2% revenue, Oxford NAV -22% QoQ). Portfolio implications: overweight AI/cloud leaders amid sector rotation; monitor semiconductor recovery and bankruptcy risks in adjacent media.

12 high priority 31 medium 43 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 29, 2026

Across 38 filings from NASDAQ-100 and related constituents, Big Tech dominates with robust revenue growth (e.g., Meta +33% YoY, Alphabet +22% YoY, Microsoft +18% YoY, Amazon +17% YoY) fueled by AI, cloud, and ads, though offset by surging capex (Meta $125-145B FY26, up from prior) and flat margins; cyclical sectors show mixed results with declines in handsets (Qualcomm -13% YoY) and media (Cumulus -12.2% YoY amid bankruptcy). Period-over-period trends reveal 12/20 earnings reporters posting YoY revenue growth averaging +15%, but margins compressed in 8 cases (avg -50 bps) due to opex/investments; guidance raised in 6 firms (ADP to 6-7% rev, SBA AFFO $11.93-12.38). Capital allocation remains shareholder-friendly with dividend hikes (CPKC +17.5%, Alphabet +5%), massive buybacks (Qualcomm new $20B auth, MSFT $10.2B returned), and compliance wins (MultiSensor AI Nasdaq regain). Portfolio-level patterns highlight AI-driven outperformance in cloud (Azure +40%, AWS +28%, Google Cloud +63%) vs weakness in traditional media/auto handsets; implications favor long tech/AI exposure but monitor capex drag and bankruptcy spillovers.

12 high priority 26 medium 38 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 29, 2026

Across 50 SEC filings from the USA S&P 500 Financials stream (including banks, insurers, fintech, and adjacent sectors), Q1 2026 results dominate with 65% showing YoY revenue growth averaging +15% (e.g., Visa +17%, Robinhood +15%, Central Pacific deposits +1.6%), but margins compressed in 55% of cases by avg -50 bps due to higher opex and provisions. Financials exhibit stable balance sheets with deposit/asset growth (Central Pacific assets +1.2% QoQ) and robust capital returns (buybacks/dividends in 40% of filings, totaling >$3B across entities like SiteOne $20M, News Corp $1B program). M&A activity surges with 6 deals (Woori share exchange Aug 11, Mission-Calavo July close, Biogen-Apellis), while guidance mixed: 30% raised (Constellium EBITDA to $900-940M), 20% cut (Humana EPS to $8.36, GE HealthCare margin to 15.4-15.7%). Insider activity absent in data, but management conviction via buybacks strong; sentiment mixed (45% mixed, 25% positive). Portfolio trend: Financials resilient amid NIM stability (Central Pacific 3.53%), but insurers face benefit ratio pressures (Humana 89.4%). Key implication: Favor banks/fintech with deposit growth and capital returns over insurers with guidance cuts; watch Q2 catalysts for margin recovery.

23 high priority 27 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 29, 2026

Across 50 SEC filings from diverse sectors (limited true S&P 500 Consumer Staples exposure, e.g., Philip Morris), Q1 2026 results dominate with mixed sentiment in 70% of cases, showing average revenue growth of +18% YoY in 14/20 reporters (e.g., Welltower +38%, Glaukos +41%, Lemonade +71%) offset by net losses in 9/15 cases and margin volatility. Key trends include EBITDA improvements (Constellium +93%, Delek Logistics +7.4%) and guidance raises in 5 companies (Constellium to $900-940M EBITDA, Glaukos to $620-635M sales, Ford to $8.5-10.5B EBIT), alongside capital returns via dividends (10+ firms, e.g., Delek Logistics +1.8%) and buybacks (Clarivate $18.1M, Lakeland 337k shares). Declines evident in solar (JinkoSolar rev -29% YoY, margins to 2.2%) and tech/services (Clarivate -1.4%, Teladoc -2%). Debt management proactive (Clarivate retired $143M at 10% discount, no debt at Glaukos), but legal risks (Atkore $136.5M settlement) and delistings (Sangamo) loom. Portfolio implications: Favor outperformers with raised guidance and FCF positivity for near-term alpha; caution on loss-widening names amid macro pressures; monitor June AGMs and late-April earnings calls for catalysts.

23 high priority 27 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 29, 2026

Across 50 SEC filings from diverse sectors (labeled S&P 500 Industrials but including pharma, energy, banks, and industrials), Q1 2026 results reveal broad revenue growth averaging +10% YoY in 28/35 reporting companies (e.g., Tradeweb +21%, GE HealthCare +7%, IDEX +9%), driven by pricing, acquisitions, and segment strength, though organic growth lagged at +3-5% in many. Margins showed mixed trends with 18/35 companies reporting compression averaging -80 bps (e.g., Stanley Black & Decker adj EBITDA -50 bps, GE HealthCare adj EBIT -150 bps), offset by expansions in outliers like Lemonade gross margin to 39% (+YoY). Guidance was raised by 12 companies (e.g., Bunge adj EPS to $9.00-$9.50 from $7.50-$8.00, IDEX organic sales to 3-4%), signaling management confidence amid M&A (Biogen-Apellis, GE-Intelerad) and capital returns ($76M IDEX buybacks, $57M Prosperity repurchases). Capital allocation leaned toward dividends/buybacks in 15 filings (e.g., Delek Logistics +1.8% distribution), with divestitures bolstering balance sheets (Stanley $1.6B net CAM proceeds). Portfolio-level patterns include 7/10 industrials (Stanley, IDEX, Generac) beating organic growth expectations, but energy/utilities mixed (OGE net income -20% YoY). Key implications: tactical buys in guidance-raisers, caution on margin squeezes; catalyst-rich with FDA PDUs and earnings calls imminent.

18 high priority 32 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — April 29, 2026

Across 21 filings in the USA S&P 500 Energy stream (including adjacent sectors), Q1 2026 results reveal mixed performance with 7/10 reporting companies showing YoY revenue growth averaging 20% (e.g., ONEOK +19.6%, Southern Copper +36.2%, Phillips 66 +6.9%), but net income volatility including sharp declines at Phillips 66 (-57.5% to $207M) and SLB (-5.6% to $752M) amid higher costs and impairments. Capital allocation trends emphasize shareholder returns, with dividend hikes (John Marshall +20% to $0.09, Phillips 66 +7%, Southern Copper $1.00/share + stock dividend) and buybacks (John Marshall 103k shares, MAA 0.6M shares for $73M, SLB $451M). Energy names like ONEOK and Southern Copper demonstrate outperformance with EPS growth (+18% and implied strength), while non-energy outliers like banks (John Marshall NIM +29bps YoY, Winchester +52bps) and Xometry (+26% revenue) signal broader financial resilience. Leadership transitions at Southern Copper (new CEO Leonardo Contreras) and Xometry (effective July 1, 2026) pose execution risks/opportunities. Forward guidance remains stable (MAA Core FFO unchanged $8.37-$8.69), with catalysts like AGMs in June and project milestones (Phillips Iron Mesa Q1 2027) driving near-term actionability. Portfolio-level theme: Margin expansion in deposits/loans contrasts energy working capital strains, favoring midstream/mining over refining/services.

9 high priority 12 medium 21 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 29, 2026

Across 50 SEC filings from Dow Jones 30 stream entities on April 29, 2026, Q1 2026 reveals resilient revenue growth averaging +9% YoY in 25+ reporting companies (e.g., Visa +17%, Yum China +10%, Evercore +100%), offset by declines in cyclical/tech names (Clarivate -1.4%, JinkoSolar -29% YoY). Margin trends mixed with expansions in industrials (Vulcan +40bps to 25.5%) and compressions in solar/manufacturing (JinkoSolar gross margin -1380bps to 2.2%), while Adjusted EBITDA grew +15% avg in positives like Generac (+29% to 18.3%). Capital allocation emphasizes returns: $11.7B Visa buybacks/dividends over 6mo, multiple guidance raises (Bunge EPS $9-9.50 from $7.50-8.00, Hayward +5% sales). No notable insider trading patterns, but M&A active (Prosperity-Stellar July 1 close, Veralto In-Situ $426M). Sentiment mixed (28/50), with bullish catalysts in AI (Kopin $15M order) and compliance resolutions (MultiSensor Nasdaq). Portfolio implication: overweight financials/consumer staples amid blue-chip stability, monitor solar/credit risks.

16 high priority 34 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 29, 2026

Across 50 filings from the USA S&P 500 Consumer Discretionary stream (broadly including adjacent financials, retail, restaurants), Q1 2026 results reveal robust revenue growth averaging 12% YoY in reporting companies (e.g., Yum China +10%, Tradeweb +21%, Chefs' Warehouse +11%, Virtu +31%), driven by volume expansion, new stores, and ADV records, but margins were mixed with compression in 7/15 key filers (avg -50 bps) due to higher costs, provisions, and restructuring. Capital allocation remains shareholder-friendly with $1B+ in repurchases/dividends (e.g., Robinhood $250M buybacks, Central Pacific $10.5M shares), alongside M&A activity like OppFi's $130M accretive bank acquisition (25%+ EPS growth 2027) and Woori's full ownership of Tongyang. Financials dominate with asset/deposit growth (avg +10% QoQ in banks like Coastal +19.5%), but credit risks emerge (NPAs up in 4/10 banks, Fannie multifamily delinquencies +4 bps to 0.78%). Restaurants show resilience (Yum! Brands system sales +6% ex-FX, 636 net new Yum China stores), while auto/rental (Avis +4% rev but EBITDA loss widening) lags. Forward guidance stable-to-raised in outperformers (Urban Edge FFO up, Chefs' $4.35-4.45B sales), signaling portfolio-level recovery potential amid volatility; watch Q2 catalysts for margin inflection.

11 high priority 39 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 29, 2026

Across 50 SEC filings primarily from financials, insurers, and select S&P 500 Healthcare names like Humana, Biogen, and Regeneron (despite broader scope), Q1 2026 results show robust revenue growth averaging +15-20% YoY in reporting firms (e.g., Regeneron +19%, Humana +23.5%, Tradeweb +21%), but mixed profitability with net income/EPS declines in 60% of cases due to higher provisions, R&D, and costs (e.g., Humana EPS -4.6% YoY, Regeneron NI -10%). Healthcare highlights include product growth (Biogen LEQEMBI +74% YoY, Regeneron Dupixent +33%) offset by legacy declines (Biogen SPINRAZA -12%), with M&A activity (Biogen-Apellis, Woori-Tongyang) signaling consolidation. Capital returns strong via buybacks (Regeneron $3B auth., multiple banks repurchasing) and dividends (e.g., Coastal $0.29 Q2), but credit risks emerge in banks (NPAs up in Citizens, Coastal provisions +$3.4M QoQ). Sentiment mixed/neutral in 70% filings, with positive M&A/earnings beats countered by guidance cuts (Humana GAAP EPS to $8.36 from $8.89). Portfolio trend: financials outperform healthcare on NIM stability (avg 3.5-3.7%), but healthcare catalysts like approvals (Regeneron EYLEA HD, Otarmeni) offer upside. Implications: favor growth biotechs over payers amid margin pressures; monitor bank credit provisions for sector spillovers.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 28, 2026

Across 27 filings in the USA S&P 500 Technology intelligence stream, a dominant theme emerges from multiple 13F-HR disclosures showing overwhelming institutional conviction in core tech names like Nvidia, Broadcom, Apple, Amazon, and Alphabet, with top holdings exceeding $1B in several portfolios and tech/semicon comprising 20-40% of allocations. Non-tech filings reveal mixed results: REITs like AvalonBay posted 40% YoY EPS growth but FFO declines and expense inflation, while banks such as Camden National surged 200% YoY net income amid deposit growth yet faced QoQ NIM compression of 5 bps. Forward-looking catalysts cluster in May 2026 (SPAC merger vote/close) and EOY 2026 (biotech trial data), with capital returns strong via $198M AvalonBay buybacks and Camden repurchases/dividends. Tech-specific signals include director departures at Intuit and Ribbon Communications (high risk), Knowles 10-Q metrics pending deeper review, and institutional passives overweighting growth tech/ETFs. Portfolio-level trends highlight tech resilience amid broader sector volatility, with 5/7 detailed earnings showing YoY beats but QoQ softening (avg net income -3% linked quarter). Actionable now: overweight tech on institutional flows, monitor SPAC redemptions and REIT guidance tweaks for relative outperformance.

11 high priority 16 medium 27 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 28, 2026

Across 37 SEC filings from NASDAQ-100 constituents and related entities on April 28, 2026, dominant themes include mixed Q1 2026 results for REITs and regional banks—strong YoY EPS growth (AvalonBay +40.4%, Camden National +200%) offset by QoQ declines, margin compression (NIM -5 bps, op ex +4.7%), and elevated expenses—amid ongoing developments and capital returns. Biotech/pharma shines with Immunic's CMO appointment advancing phase 3 MS trials (data E2026) and Gilead's $7.1B Arcellx acquisition completion (77.2% tendered at $115/share + CVR). SPAC activity peaks with AParadise merger deadlines (Apr 29 non-redemption, May 1 vote, May 7 close), while 13F filings reveal institutional tech overweight (e.g., Fukoku's $195M Broadcom, National Mutual's $89M Nvidia). Capital allocation favors buybacks (AvalonBay $198M, Camden 33k shares) and dividends, with REIT Net Debt/EBITDA ~4.8x and bank CET1 >12%. Portfolio trends flag REIT NOI stagnation (AvalonBay +0.2%), bank deposit growth (Camden +1% QoQ), and M&A upside (Arcellx CVR to 2030). Actionable implications: Biotech catalysts for alpha, SPAC arbitrage near-term, caution on REIT expense trends and director departures (Intuit, Ribbon).

14 high priority 23 medium 37 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 28, 2026

Across 50 filings from S&P 500 Financials and related sectors on April 28, 2026, Q1 2026 earnings dominate with 20+ companies reporting average revenue growth of 12% YoY (e.g., PJT Partners +29%, Bread Financial +6% NII), but profitability mixed as 8/15 showed net losses or declines due to higher costs/fuel (e.g., JetBlue op loss -10% margin, Shutterstock -18% rev). Margin trends split: expansions in 6/12 (Bread NIM +119bps, Polaris GP +423bps) vs compressions in 5/12 (Allegion -200bps adj). Capital allocation robust with $1B+ buybacks (PJT $244M, Pentair $200M, American Tower $184M) and dividend hikes (Pentair 50th year +8%, Enterprise +2.8%). M&A catalysts abound (RE/MAX merger, Ligand/XOMA accretive, CECO/Thermon June close), with 7/10 guidances raised (Centene EPS >$3.40, Curbline OFFO $1.20-1.23). Insider conviction mixed (high ownership Lindblad 26%), 13Fs show tech-heavy tilts (China Universal NVIDIA top). Portfolio trend: Resilient growth amid costs, bullish forward outlooks signal upside for cyclicals/financials.

17 high priority 33 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 28, 2026

Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (with broader cross-sector insights), key themes include modest revenue growth averaging 5-10% YoY in staples like beverages (CCEP +6.7%, KO +12%) offset by pricing/margin pressures (KMB gross margin -60bps, UPS US Domestic rev -2.3%), mixed sentiments in 60% of detailed reports, and positive volume drivers (CCEP +8.5% unit cases, KO +3%). Capital allocation favors shareholder returns with buybacks (Valmont $57.5M, Asbury $147M) and dividend hikes (First Commonwealth +3.7%), while forward guidance shows resilience (Omnicell raised FY EBITDA to $153-168M, GM raised FY EBIT to $13.5-15.5B). Outliers include strong international growth (KMB Intl Personal Care +9.1%) amid US softness, and neutral institutional 13F holdings signaling stability. Portfolio-level trends highlight margin compression in 4/7 earnings reports (avg -100bps) but operating leverage in others (Valmont op inc +21.3%), implying defensive positioning in staples amid economic uncertainty. Critical developments like KO value share gains and Omnicell 15% rev growth offer near-term catalysts, while risks from originations declines (GM Financial -15% YoY) warrant caution.

14 high priority 36 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 28, 2026

Across 50 SEC filings from S&P 500 Industrials and related streams dated April 28, 2026, Q1 2026 results reveal mixed performance with transportation/industrials showing revenue resilience (e.g., ArcBest +3.2% YoY to $998.8M, Avery Dennison +7% to $2.3B) amid tonnage/shipment growth but margin pressures (ArcBest OR 97.3% vs 95.9%, UPS U.S. Domestic op profit -47% to $515M). Biotech/pharma subsets shone with guidance raises (Ligand rev to $270-310M post-XOMA acquisition, Axogen 20%+ FY growth) and catalysts (Rocket $180M PRV sale), while media/real estate faced headwinds (Shutterstock rev -18% YoY, reAlpha -9%). Capital allocation remains shareholder-friendly with $860M returns at Hilton, $133M at Avery, UPS $5.4B FY dividends; 13F filings highlight institutional tech/ETF bias (e.g., China Universal NVIDIA $81M top). Overarching themes include accretive M&A (Ligand, Real Brokerage scaling agents 5x), cost savings (UPS $600M Q1), and pending regulatory hurdles (Shutterstock-Getty CMA deadline June 14). Portfolio-level trends: 7/12 earnings reporters posted YoY rev growth averaging +10% but 5 saw op margin compression (-150bps avg); forward catalysts cluster in H2 2026 (deal closes, trials). Implications: Tactical buys in growth industrials/biotech, caution on volume-dependent transports amid softening demand.

14 high priority 36 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — April 28, 2026

Across 16 filings in the S&P 500 Energy stream (with some cross-sector context), key themes include stable capital returns from energy leaders like Cheniere amid sparse sector-specific updates, robust Q1 growth at Sherwin-Williams despite soft end-market demand, and M&A momentum via SPAC mergers and acquisitions like Real Brokerage's RE/MAX deal. Period-over-period trends show Sherwin-Williams net sales +6.8% YoY to $5.67B and EPS +7.5% to $2.15, alongside net income +6.1% YoY in its 10-Q, but offset by declines in residential/DIY sales and negative working capital; Hallmark Venture narrowed losses but reported zero revenue for second year with massive share dilution. Cheniere Energy Partners and Inc. declared steady quarterly distributions/dividends ($0.790/unit and $0.555/share), signaling shareholder-friendly capital allocation. 13F filings reveal sustained institutional conviction in Chevron (top holding for Cherokee Insurance at $11.4M and Abel Hall), while SPAC AParadise eyes May 7 merger close. Overall sentiment mixed-positive with energy stability contrasting growth headwinds elsewhere; actionable catalysts cluster in early May for distributions and M&A votes.

7 high priority 9 medium 16 total filings